Beijing Biostar Pharmaceuticals Co., Ltd.

北京华昊中天生物医药股份有限公司

02563.HK

Develops oncology drugs using synthetic biology and microbial metabolite technology platforms. Its commercialized product, Utidelone Injection, approved by the NMPA in 2021, treats relapsed or metastatic breast cancer, with 19 pipeline candidates covering various solid tumors in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Distribution model
• Single product, business line or region
• Pricing policy and price changes
• Particular sales arrangements
• Capacity and utilisation
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Investments and fair-value assets
• Adverse change after the track record
• Non-recurring gains and losses
• Chapter 18A biotech